Scarring Alopecia Is Driven by the Collapse of EGFR-Protected JAK-STAT1-Sensitive Stem Cell Immune Privilege
November 2023
in “
The journal of investigative dermatology/Journal of investigative dermatology
”
TLDR Cancer treatment drugs can cause permanent hair loss by damaging hair follicle stem cells, but a specific inhibitor might reverse this effect.
Long-term treatment with EGFR inhibitors can lead to inflammatory scarring alopecia by causing hyper-activation of JAK-STAT1 signaling, which collapses the immune privilege of hair follicle stem cells. A mouse model with hair follicle-specific deletion of EGFR showed that therapeutic inhibition of JAK1/2 can restore immune privilege and stimulate hair growth. Translational studies confirmed STAT1 pathway activation in patients treated with EGFR inhibitors and those with certain types of alopecia. A case study demonstrated successful treatment of folliculitis decalvans with the JAK1/2 inhibitor Baricitinib, suggesting potential therapeutic strategies for scarring alopecia linked to EGFR-inhibitor therapy.